A recent study presented at the European Academy of Dermatology and Venereology found that people using GLP-1 drugs like Ozempic and Mounjaro are nearly 25% more likely to experience nail disorders compared to those not on these medications. Specifically, 39% of users reported nail detachment, a condition where nails separate from the nail bed, compared to just 9% in controls. The study also noted higher incidences of hair loss and scalp inflammation among GLP-1 users, suggesting that while weight loss might be partly responsible for these side effects, there may be additional factors at play related to the drugs themselves.
Written locally by qwen2.5:14b on 2026-10-08,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
A new study presented at the European Academy of Dermatology and Venereology found that people using GLP-1 drugs like Ozempic and Mounjaro were nearly 25% more likely to experience nail disorders than those not on these medications. Specifically, 39% of GLP-1 users reported nail detachment compared to just 9% in the control group. This condition involves the nail separating from the nail bed and cannot be reattached, requiring several months or over a year for regrowth. Additionally, two-thirds of GLP-1 users experienced at least one type of nail disorder, including discoloration, which was observed 2.7 times more frequently in those on the medication compared to controls. The study's lead author, Charles Taïeb, noted that while there is a clear association between GLP-1 use and these conditions, it’s important to consider other factors such as pre-existing dermatological issues and weight loss when evaluating causation.
Written for “GLP-1 Side Effects” on 2026-10-08,
grounded in this article and the 0 other(s) covering the same event.
Ozempic and Mounjaro can cost an arm and a leg — and maybe a fingernail.
asserted
Ozempic → cost → arm
A new study found that people on GLP-1 drugs were nearly 25% more likely to experience a nail disorder than those not on the drugs.
asserted
people → find → drugs
And one particularly squirm-inducing problem was over four times more likely to appear in GLP-1 users.
asserted
problem → induce → users
The new study, presented at the European Academy of Dermatology and Venereology, found that 39% of GLP-1 users reported nail detachment — when the finger or toe nail separates from the nail bed — compared to just 9% of controls.
asserted
nail → present → controls
Once it’s detached, the nail can’t be reattached.
asserted
nail → detach → ?
It’ll take several months or over a year to regrow.
asserted
It → take → months
But that’s not all.
asserted
that → ’ → ?
Researchers report two thirds of GLP-1 users report at least one nail disorder, including nail discoloration — which appeared 2.7 more frequently in those on the meds.
asserted
which → report → meds
“Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal,” said study author Charles Taïeb.
asserted
Taïeb → associate → therapies
Do GLP-1s cause nail problems?
asserted
GLP-1s → cause → problems
In trials, GLP-1s have shown to cause up to 22% weight loss — while real-world loss is more around 2-8% in a year.
asserted
loss → show → year
That weight loss can cause nail problems, though, from slower growth to brittle nails.
asserted
loss → cause → nails
This is connected to nutritional deficiencies as a result of less eating, and dehydration.
asserted
This → connect → eating
Researchers of the new study can’t say for sure whether it’s the meds causing nail issues, or primary effects like weight loss.
asserted
it → say → loss
While researchers did try to adjust the results accounting for existing dermatological conditions, nutritional deficiencies, and weight loss, nail detachment and discoloration still showed up two to three times as often with GLP-1 users.
“Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself,” Taïeb said.
asserted
Taïeb → try → treatment
Nail and hair loss
A companion study with the same participants in the first showed that hair loss was also significantly higher in those on a GLP-1 drug.
asserted
loss → show → drug
Unusual hair loss (noticeable shedding) was reported by 50% of GLP-1 users compared to 34% in those not on the drug.
asserted
loss → report → drug
Loss in volume or density (overall less hair that remains) was more than twice as common in those on the jab, and scalp redness was around three times as common.
asserted
redness → remain → jab
Hair loss on GLP-1s are a known phenomenon.
asserted
loss → know → GLP-1s
Experts say that it’s “almost always” temporary and a reaction to weight loss and rapid physical changes.
asserted
it → say → loss
Authors of this study believe that something more than weight loss is at play, though.
asserted
something → believe → play
They note that hair loss was usually accompanied by itching, redness, or scaling — a sign that there’s “an inflammatory component” at play.
asserted
loss → note → play
“Scalp inflammation was the rule rather than the exception, which clinicians do not currently look for and which may be treatable,” explained author Dr. Bruno Halioua.
uncertain
Halioua → look → which
Doctors can prescribe special shampoos and topical medications to address inflammation on the scalp.
asserted
Doctors → prescribe → scalp
Authors stress these new results should be for “awareness rather than alarm.”
asserted
results → stress → awareness
Hair and nail loss, at the end of the day, is aesthetic and temporary, while weight loss has a huge long-term impact on many aspects of health.
asserted
loss → have → health
“These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one’s own initiative,” Halioua said.
asserted
Halioua → stop → initiative
“Anyone who notices hair shedding, an itchy or red scalp or nail changes should mention it to their doctor rather than discontinue therapy.”
asserted
who → notice → therapy
The Aporia
